Loading the records…
Loading the records…
HR11141 proposes a temporary exemption for buprenorphine from the DEA's Suspicious Orders Report System. The bill is in early stage with no cosponsors. If enacted, it would provide marginal regulatory relief to buprenorphine manufacturers like Indivior ($INDV), but the impact is small and temporary.
The bill does not alter the competitive landscape for major healthcare companies. Indivior may see a slight reduction in compliance costs, but the effect is too small to drive significant stock movement. Investors should focus on broader opioid policy trends rather than this narrow exemption.
HR11141, introduced by Rep. Tonko (D-NY) on November 20, 2026, is a narrow bill that would require the DEA Administrator to temporarily exempt buprenorphine from the Suspicious Orders Report System (SORS) for the remainder of the opioid public health emergency. The bill has been referred to the Committees on Energy and Commerce and the Judiciary, indicating an early legislative stage. With no cosponsors and no further action, the bill currently has low momentum.
The mechanism is straightforward: by removing buprenorphine from SORS reporting, the DEA would reduce the regulatory burden on registrants who handle this controlled substance. This could lower compliance costs for manufacturers, distributors, and dispensers, and potentially encourage wider distribution of buprenorphine, a key medication for opioid use disorder treatment. However, the exemption is explicitly temporary, tied to the ongoing public health emergency, which limits its long-term impact.
The primary corporate beneficiary would be Indivior, a pure-play addiction treatment company whose revenue is heavily concentrated in buprenorphine products (Suboxone film, Sublocade injection). The exemption would reduce Indivior's compliance overhead and could support sales volume if distribution barriers ease. However, the cost savings are likely a small fraction of Indivior's revenue, and the temporary nature of the exemption caps the financial upside. Larger healthcare companies in the provided data ($JNJ, $LLY, $UNH) have minimal or no direct exposure to buprenorphine, so the bill does not materially affect their outlook.
Legislatively, the path forward is uncertain. The bill must clear two committees and gain cosponsors to build momentum. Given the narrow scope and lack of bipartisan sponsorship, passage in the 119th Congress is unlikely without broader opioid policy packaging. Investors should monitor for committee hearings or markup as signals of progress, but the current status suggests no near-term market impact.
Matched on shared policy language across AI analyses, with ticker & timing weight
A bill to require the Administrator of the Drug Enforcement Administration to temporarily exempt buprenorphine from the Suspicious Orders Report System for the remainder of the opioid public health emergency.
MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES: $111M Department of Health and Human Services Grant
MENTAL HEALTH & SUBSTANCE ABUSE SERVICES, TENNESSEE DEPARTMENT OF: $95.1M Department of Health and Human Services Grant
Executive orders & memoranda affecting the same sectors or companies
This executive order requires all federal contractors and subcontractors to notify the White House and relevant agencies of any congressional requests related to their work with the executive branch, and to follow instructions to withhold information deemed protected by executive privilege. It directs agencies to enforce these requirements through contract termination or debarment, and tasks the Office of Management and Budget with developing implementation guidance. The order aims to protect executive branch confidentiality and enhance efficiency in federal contracting by preventing uncoordinated disclosures to Congress.
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →